These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30957991)

  • 1. Drug Delivery Strategies for the Treatment of Metabolic Diseases.
    Shi S; Kong N; Feng C; Shajii A; Bejgrowicz C; Tao W; Farokhzad OC
    Adv Healthc Mater; 2019 Jun; 8(12):e1801655. PubMed ID: 30957991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases.
    Cao Y
    Nat Rev Drug Discov; 2010 Feb; 9(2):107-15. PubMed ID: 20118961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage-Targeted Therapeutics for Metabolic Disease.
    Peterson KR; Cottam MA; Kennedy AJ; Hasty AH
    Trends Pharmacol Sci; 2018 Jun; 39(6):536-546. PubMed ID: 29628274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Target Drugs Against Metabolic Disorders.
    Scotti L; Scotti MT
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):389-390. PubMed ID: 31274061
    [No Abstract]   [Full Text] [Related]  

  • 5. Transdermal Drug Delivery Systems and Their Use in Obesity Treatment.
    Li Z; Fang X; Yu D
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting bile-acid signalling for metabolic diseases.
    Thomas C; Pellicciari R; Pruzanski M; Auwerx J; Schoonjans K
    Nat Rev Drug Discov; 2008 Aug; 7(8):678-93. PubMed ID: 18670431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral nanomedicine approaches for the treatment of psychiatric illnesses.
    Dening TJ; Rao S; Thomas N; Prestidge CA
    J Control Release; 2016 Feb; 223():137-156. PubMed ID: 26739547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric Carriers for Controlled Drug Delivery in Obesity Treatment.
    Huang D; Deng M; Kuang S
    Trends Endocrinol Metab; 2019 Dec; 30(12):974-989. PubMed ID: 31668904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Target Drugs Against Metabolic Disorders.
    Scotti L; Monteiro AFM; de Oliveira Viana J; Mendonça Junior FJB; Ishiki HM; Tchouboun EN; Santos R; Scotti MT
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):402-418. PubMed ID: 30556507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric nanoparticle drug delivery technologies for oral delivery applications.
    Pridgen EM; Alexis F; Farokhzad OC
    Expert Opin Drug Deliv; 2015; 12(9):1459-73. PubMed ID: 25813361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy.
    Tobin JF; Freedman LP
    Trends Endocrinol Metab; 2006 Sep; 17(7):284-90. PubMed ID: 16870465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR120 agonism as a countermeasure against metabolic diseases.
    Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
    Drug Discov Today; 2014 May; 19(5):670-9. PubMed ID: 24315954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction-responsive polymers for drug delivery in cancer therapy-Is there anything new to discover?
    Monteiro PF; Travanut A; Conte C; Alexander C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Mar; 13(2):e1678. PubMed ID: 33155421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine.
    Wang S; Xu Z; Cai B; Chen Q
    Endocr Metab Immune Disord Drug Targets; 2021; 21(6):971-979. PubMed ID: 32914727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.
    Finan B; Clemmensen C; Zhu Z; Stemmer K; Gauthier K; Müller L; De Angelis M; Moreth K; Neff F; Perez-Tilve D; Fischer K; Lutter D; Sánchez-Garrido MA; Liu P; Tuckermann J; Malehmir M; Healy ME; Weber A; Heikenwalder M; Jastroch M; Kleinert M; Jall S; Brandt S; Flamant F; Schramm KW; Biebermann H; Döring Y; Weber C; Habegger KM; Keuper M; Gelfanov V; Liu F; Köhrle J; Rozman J; Fuchs H; Gailus-Durner V; Hrabě de Angelis M; Hofmann SM; Yang B; Tschöp MH; DiMarchi R; Müller TD
    Cell; 2016 Oct; 167(3):843-857.e14. PubMed ID: 27720451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G protein-coupled receptors for energy metabolites as new therapeutic targets.
    Blad CC; Tang C; Offermanns S
    Nat Rev Drug Discov; 2012 Aug; 11(8):603-19. PubMed ID: 22790105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment.
    Liu G; Lovell JF; Zhang L; Zhang Y
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications.
    Ruttala HB; Ramasamy T; Madeshwaran T; Hiep TT; Kandasamy U; Oh KT; Choi HG; Yong CS; Kim JO
    Arch Pharm Res; 2018 Feb; 41(2):111-129. PubMed ID: 29214601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
    Dobrzyn P; Dobrzyn A
    Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.